Charisse Flerida A. Pasaje

Shared Binding Site but Divergent Resistance Profiles Uncover Novel Resistance Mechanisms in Plasmodium HSP90 Inhibitors

This study identifies divergent resistance mechanisms in Plasmodium HSP90 inhibitors despite shared binding sites, showing that enhanced binding can paradoxically correlate with resistance.

The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity Against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation

This study shows that CHIR-124, a human Chk1 inhibitor, is active against Plasmodium falciparum through dual inhibition of PfArk1 and hemozoin formation, suggesting polypharmacology as a strategy for antimalarial drugs.

Targeting Aurora kinases as essential cell cycle regulators to deliver multi-stage antimalarials against Plasmodium falciparum

The paper identifies PfArk1 as a key target for antimalarial drugs by showing that inhibiting it disrupts parasite mitosis and nuclear division.

Identification of Antimalarial Compounds that Inhibit Apicomplexan AP2 Proteins in the Human Malaria Parasite Plasmodium falciparum

The paper identifies antimalarial compounds that inhibit ApiAP2 proteins in Plasmodium falciparum by screening small molecules against the AP2-EXP domain and validating their effects on parasite gene regulation and growth.